Corresponding Author	Jens Panse
List all other authors	Nathan A. Boggs, Lindsay Rein, Prithviraj Bose, Brian D. Modena, Vito Sabato, Karin Hartmann, Cem Akin, Tracy I. George, Cecilia Arana Yi, Hanneke Oude Elberink, Deepti H. Radia, Andreas Reiter, Miguel Piris-Villaespesa, Ingunn Dybedal, Stephen T. Oh, Pankit Vachhani, Anthony M. Hunter, Mariana Castells, Cristina Livideanu, Paul van Daele, Arnold Kirshenbaum, Iván Alvarez-Twose, Jennifer E. Vaughn, Minakshi Taparia, Sonia Cerquozzi, Andrzej Mital, Marek Hus, Alessandra Romano, John M. Fahrenholz, Frederick Lansigan, Cristina Papayannidis, Helena Pomares-Marin, Michela Rondoni, Celalettin Ustun, Richard Herrscher, Amanda Pilla, Jenna Zhang, Lei Sun, Nisha Shah, Hina Jolin, Rachael Easton, Jessica Sachs, Frank Siebenhaar, Daniel J. DeAngelo
Email-Address	jpanse@ukaachen.de
Institute/Department	Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany
Address of Institute	Pauwelsstraße 30, 52074 Aachen, Germany
Title of Presentation	Expanded Results From the Phase 2 Summit Trial: Bezuclastinib in Adults With Non-Advanced Systemic Mastocytosis
abstract-hint	
Abstract of Presentation	Background: Non-advanced systemic mastocytosis (NonAdvSM) is driven by KIT c.2447 C>T (p.D816V) in >95% of cases. NonAdvSM patients have persistent symptoms that impair quality of life despite best supportive care therapies. Bezuclastinib, an oral, potent, type 1 tyrosine kinase inhibitor with selective activity against KIT D816V, is being investigated in patients with NonAdvSM in the Summit trial. Methods: Summit (NCT05186753) is a multicenter, randomized, double-blind, placebo-controlled phase 2 trial in

	patients with NonAdvSM who had inadequate symptom control despite best supportive care. Primary endpoint: 24-week mean change from baseline in Mastocytosis Symptom Severity Daily Diary (MS2D2) total symptom score (TSS) (range: 0-110), a patient-reported outcome measure of NonAdvSM symptom severity. Key secondary endpoints: proportion of patients with ≥50% reduction in serum tryptase, KIT p.D816V variant allele frequency, bone marrow mast cell (MC) burden, MS2D2 TSS improvement, and ≥30% MS2D2 TSS reduction. Results: As of May 22, 2025, 179 patients, representative of the NonAdvSM population with moderate to severe symptoms, were enrolled in part 2. Mean baseline MS2D2 TSS was 55.6 (SD: 19.8). At week 24, bezuclastinib led to significantly greater symptom improvement vs placebo (LS mean MS2D2 TSS change: -24.3 vs -15.4; placebo-adjusted difference: -8.9 points; P=0.0002). All primary and key secondary endpoints were met. Most treatment-emergent adverse events were low grade (70% grade 1) and reversible. Conclusions: Bezuclastinib demonstrated statistically and clinically significant improvements in MC disease and symptom burden vs placebo in patients with NonAdvSM. The treatment was generally well tolerated. Expanded data from Summit will be presented.